<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Medicare Part D Analysis | Aiden B. Jajo</title>
    <link rel="stylesheet" href="styles.css">
    <link rel="stylesheet" href="project-styles.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:wght@300;400;600&family=Work+Sans:wght@300;400;500&display=swap" rel="stylesheet">

</head>
<body>
    <!-- Navigation -->
    <nav class="nav">
        <div class="nav-container">
            <a href="index.html" class="nav-logo">Aiden B. Jajo</a>
            <div class="nav-links">
                <a href="index.html#about" class="nav-link">About</a>
                <a href="index.html#projects" class="nav-link">Projects</a>
                <a href="index.html#goals" class="nav-link">Goals</a>
                <a href="index.html#resume" class="nav-link">Resume</a>
                <a href="index.html#contact" class="nav-link nav-link-cta">Contact</a>
            </div>
        </div>
    </nav>

    <!-- Project Hero -->
    <section class="project-hero">
        <div class="container">
            <div class="breadcrumb">
                <a href="index.html">Home</a> / <a href="index.html#projects">Projects</a> / <span>Medicare Part D Analysis</span>
            </div>
            <h1 class="project-hero-title">The Billion-Dollar Opportunity in Medicare Part D</h1>
            <p class="project-hero-subtitle">Why are Medicare beneficiaries paying billions more than necessary when equally effective generic alternatives exist?</p>
            <div class="project-meta">
                <span class="meta-item"><strong>Tools:</strong> Python, Pandas, Tableau</span>
                <span class="meta-item"><strong>Dataset:</strong> 70,000+ prescription records (1.39B total claims, 2023)</span>
                <span class="meta-item"><strong>Focus:</strong> Cost Savings Analysis</span>
            </div>
        </div>
    </section>

    <!-- Executive Summary -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">Executive Summary</h2>
            <div class="content-block">
                <p>This analysis examines 2023 Medicare Part D prescribing patterns across <strong>359 medications</strong> in <strong>50 states plus Washington, D.C.</strong> The dataset represents approximately <strong>1.39 billion prescription claims</strong>. The findings reveal <strong>$2.68 billion in potential annual savings</strong> if generic adoption improved by just 25%. The largest single opportunity‚Äî<strong>$885 million</strong>‚Äîcomes from three insulin products where brand-name versions are prescribed over 95% of the time despite FDA-approved alternatives. Generic adoption varies by only <strong>4.5 percentage points</strong> across states (74.4% to 78.8%), yet five states account for over <strong>$1.9 billion</strong> in potential savings. The primary barrier isn't medical necessity‚Äîit's systemic friction in how prescriptions are written and filled.</p>
            </div>
        </div>
    </section>

    <!-- Challenge Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">The Challenge</h2>
            <div class="content-block">
                <p class="lead-text">Working as a pharmacy clerk at an independent pharmacy in El Cajon, I see the same scenario play out every week: a Medicare patient hands me their prescription, I process it through their Part D plan, and their face falls when they see the copay.</p>

                <p>"Is there a cheaper version?" they ask. Sometimes there is‚Äîa generic that works exactly the same but costs a fraction of the price. Other times, their doctor specifically wrote for the brand name, and we're stuck.</p>

                <p>But here's what bothers me: even when generics are available, I see prescriptions come through for brand-name medications that could easily be swapped. An insulin prescription that costs $800 when a lower-cost alternative exists. An antipsychotic that runs $400 when the generic is $20. These aren't isolated cases‚Äîthey're patterns.</p>

                <p>Insurance pricing often feels like a black box. This project analyzes Medicare Part D prescriber data from 2023 to quantify exactly how much money is being left on the table, and where the biggest opportunities for savings exist.</p>
            </div>
        </div>
    </section>

    <!-- Methodology Section -->
    <section class="project-section bg-light">
        <div class="container">
            <h2 class="section-title-small">Data & Methodology</h2>

            <div class="methodology-grid">
                <div class="method-card">
                    <div class="method-icon">üìä</div>
                    <h3>Data Source</h3>
                    <p>I used Medicare Part D Prescriber Data from 2023, published by the Centers for Medicare & Medicaid Services (CMS). The raw dataset is over 3GB and contains prescriber-level records with key information: <code>Gnrc_Name</code> (generic drug name), <code>Is_Brand</code> (whether it's brand or generic), <code>Prscrbr_State_Abrvtn</code> (state code), <code>Tot_Drug_Cst</code> (total cost), <code>Tot_Clms</code> (total claims), and <code>Tot_Benes</code> (total beneficiaries). After filtering to include only medications that have both brand and generic versions available, 359 drugs remained for analysis. The primary geographic comparisons focus on the 50 states plus Washington, D.C., with territory codes and military addresses retained separately.</p>
                </div>

                <div class="method-card">
                    <div class="method-icon">üßπ</div>
                    <h3>Data Processing</h3>
                    <p>I organized the prescriber-level data in two ways: first by drug name and brand/generic status to create national medication profiles, and second by state and brand/generic status to build state-level cost comparisons. Where beneficiary counts were missing, I kept those gaps rather than filling them with estimates, since the claims and cost data were complete. Territory codes and military addresses were included but analyzed separately from the 50 states and D.C.</p>
                </div>

                <div class="method-card">
                    <div class="method-icon">‚öôÔ∏è</div>
                    <h3>Savings Calculation</h3>
                    <p>For each medication, I calculated potential savings using this formula:<br><br>
                    <code>Savings = Brand Claims √ó (Brand Cost per Claim ‚àí Generic Cost per Claim)</code><br><br>
                    This shows the maximum recoverable cost if every brand prescription switched to the generic equivalent at today's generic prices. I chose the <strong>25% improvement scenario</strong> as the primary focus because it's ambitious but realistic‚Äîsignificant enough to matter without requiring that every single prescription be switched. For state-level savings, I measured how far each state falls below the national average generic adoption rate (<strong>76.4%</strong>) and calculated what they could save by closing that gap.</p>
                </div>

                <div class="method-card">
                    <div class="method-icon">‚ö†Ô∏è</div>
                    <h3>Important Note on Insulin</h3>
                    <p>Most generic medications are chemically identical to their brand-name versions, which makes substitution straightforward. Insulin is more complex. Many "generic" insulin products are actually <strong>biosimilars</strong>‚Äîsimilar but not identical to the original. The FDA has approved these as safe and effective alternatives for most patients, but some doctors prefer brand-name insulin due to concerns about individual patient responses. The insulin savings figures in this analysis ($885M) assume these products can be safely substituted, which FDA guidance supports, but this may not apply universally to every patient.</p>
                </div>

                <div class="method-card">
                    <div class="method-icon">üìà</div>
                    <h3>Analysis Tools</h3>
                    <p>I used Python (pandas, numpy, matplotlib, seaborn) for data cleaning, processing, calculations, and creating static visualizations. For interactive exploration, I built a dashboard in Tableau Public that allows filtering by state and medication. All source code and processed data are available on GitHub.</p>
                </div>

                <div class="method-visual">
                    <img src="visual_2_cost_distribution.png" alt="Cost Distribution: Brand vs Generic Per-Claim Costs">
                    <p class="visual-caption">Brand medications cost significantly more per claim than generics‚Äîthis is the gap I quantified across 359 drugs</p>
                </div>

                <div class="method-visual">
                    <img src="visual_4_savings_matrix.png" alt="Savings Opportunity Matrix: Cost Difference vs Potential Savings">
                    <p class="visual-caption">Each medication plotted by cost difference and savings potential. Insulin products cluster in the high-impact quadrant</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Key Findings Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">Key Findings</h2>

            <!-- Finding 01 -->
            <div class="insight-block">
                <div class="insight-content">
                    <div class="insight-number">01</div>
                    <h3>Three Insulin Products Represent $885 Million in Potential Savings</h3>
                    <p>Insulin Aspart, Insulin Lispro, and Insulin Degludec are prescribed as brand-name versions 95 to 99% of the time despite available alternatives. These three medications alone represent the single largest savings opportunity in Medicare Part D.</p>

                    <div class="key-stats">
                        <div class="stat-item">
                            <span class="stat-value">99%</span>
                            <span class="stat-label">brand prescriptions for Insulin Aspart</span>
                        </div>
                        <div class="stat-item">
                            <span class="stat-value">$885M</span>
                            <span class="stat-label">potential savings from insulin alone</span>
                        </div>
                    </div>
                </div>
                <div class="insight-visual">
                    <img src="visual_1_top_savings.png" alt="Top 10 Medications by Savings Potential">
                    <p class="visual-caption">Top 10 medications ranked by potential annual savings with 25% generic adoption improvement</p>
                </div>
            </div>

            <!-- Finding 02 -->
            <div class="insight-block reverse">
                <div class="insight-visual">
                    <img src="visual_3_brand_generic_composition.png" alt="Brand vs Generic Composition">
                    <p class="visual-caption">Stacked bars reveal insulin's near-complete brand dominance compared to better generic adoption in other drug classes</p>
                </div>
                <div class="insight-content">
                    <div class="insight-number">02</div>
                    <h3>Brand Dominance in High-Cost Medications is Extreme</h3>
                    <p>When comparing prescription patterns for top savings-potential drugs, a clear divide emerges. Insulin products show nearly complete brand dominance while other medication classes demonstrate that high generic adoption is achievable.</p>

                    <p>This isn't about generic availability. The medications exist. This is about systemic barriers preventing their use.</p>

                    <div class="key-stats">
                        <div class="stat-item">
                            <span class="stat-value">20</span>
                            <span class="stat-label">drugs with over 90% brand prescriptions</span>
                        </div>
                        <div class="stat-item">
                            <span class="stat-value">45%</span>
                            <span class="stat-label">of total savings concentrated in those drugs</span>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Finding 03 -->
            <div class="insight-block">
                <div class="insight-content">
                    <div class="insight-number">03</div>
                    <h3>Your State Determines Your Generic Access</h3>
                    <p>Across the 50 states plus Washington, D.C., generic adoption rates range from roughly <strong>74.4% to 78.8%</strong>‚Äîonly 4.5 percentage points. This narrow spread translates to hundreds of millions in unnecessary costs and suggests the problem isn't medical necessity but regional prescribing habits. When including territory and military location codes present in the CMS file, the range widens considerably (down to 69.7% and up to 100%), which highlights the importance of separating state-level comparisons from non-state codes.</p>

                    <div class="key-stats">
                        <div class="stat-item">
                            <span class="stat-value">24</span>
                            <span class="stat-label">states below the national average (76.4%)</span>
                        </div>
                        <div class="stat-item">
                            <span class="stat-value">62.6%</span>
                            <span class="stat-label">of all state savings concentrated in just 5 states</span>
                        </div>
                    </div>
                </div>
                <div class="insight-visual">
                    <img src="visual_5_state_rankings.png" alt="State Rankings">
                    <p class="visual-caption">Top 15 and bottom 15 states by generic adoption rate. Geographic differences are significant.</p>
                </div>
            </div>

            <!-- Finding 04 -->
            <div class="insight-block reverse">
                <div class="insight-visual">
                    <img src="visual_6_state_opportunity.png" alt="State Opportunity Analysis">
                    <p class="visual-caption">States plotted by generic adoption and savings potential. Large bubbles below the national average represent the biggest opportunities.</p>
                </div>
                <div class="insight-content">
                    <div class="insight-number">04</div>
                    <h3>Five States Represent Over $1.9 Billion in Savings Opportunity</h3>
                    <p>New York alone could save nearly $978 million annually just by reaching the national average generic adoption rate of 76.4%. Indiana ($258M), Michigan ($256M), California ($222M), and Alabama ($214M) round out the top five, together representing over $1.9 billion in concentrated, geographically targetable savings.</p>
                </div>
            </div>

            <!-- Finding 05 -->
            <div class="insight-block highlight">
                <div class="insight-icon">üí°</div>
                <div class="insight-content">
                    <h3>Systemic Friction, Not Clinical Necessity, Drives Brand Use</h3>
                    <p>Working behind the pharmacy counter, I see these barriers firsthand. When a prescription comes in for a brand-name drug and I know there's a generic alternative, I can't just make the switch‚ÄîI need the prescriber's approval. So I call the doctor's office.</p>

                    <p>Sometimes I get immediate authorization. Sometimes the doctor specifically wants the brand version for clinical reasons. But often, the response is simply "that's what the doctor always writes," or the call doesn't get returned. The patient needs their medication today, so we fill the brand because that's what's written on the prescription.</p>

                    <p>This happens millions of times across the country. The $2.68 billion gap isn't driven by medical necessity‚Äîit's driven by workflow friction.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Impact & Path Forward Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">The Path Forward</h2>

            <div class="takeaway-grid">
                <div class="takeaway-card">
                    <h3>Target High-Impact Medications</h3>
                    <p>Focus immediate intervention on insulin and the top 10 medications by savings potential.</p>
                    <ul>
                        <li>Provider education campaigns highlighting generic effectiveness</li>
                        <li>Automatic substitution policies with clinical override options</li>
                        <li>Patient education at point of prescription</li>
                    </ul>
                </div>

                <div class="takeaway-card">
                    <h3>Geographic Targeting</h3>
                    <p>Pilot intensive interventions in underperforming states with large Medicare populations.</p>
                    <ul>
                        <li>New York: $978M potential savings</li>
                        <li>Indiana: $258M potential savings</li>
                        <li>Michigan: $256M potential savings</li>
                        <li>California: $222M potential savings</li>
                        <li>Alabama: $214M potential savings</li>
                    </ul>
                </div>

                <div class="takeaway-card">
                    <h3>Prescriber Feedback Systems</h3>
                    <p>Provide physicians with data-driven insights on their prescribing patterns.</p>
                    <ul>
                        <li>Generic prescription rate compared to peers</li>
                        <li>Estimated patient cost savings</li>
                        <li>Clinical outcomes demonstrating equivalency</li>
                    </ul>
                </div>

                <div class="takeaway-card" style="padding: 0; border: none; background: transparent;">
                    <img src="visual_7_waterfall.png" alt="Savings Waterfall" style="width: 100%; height: auto; border-radius: 4px;">
                    <p class="visual-caption" style="margin-top: 1rem;">Projected impact of 25% generic adoption improvement</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Dashboard Section -->
    <section class="project-section bg-dark">
        <div class="container">
            <h2 class="section-title-small light">Interactive Dashboard</h2>
            <p class="dashboard-intro">Explore the data yourself using this interactive Tableau dashboard. Filter by state, medication, and cost metrics to understand how different factors affect savings potential.</p>

            <div class="tableau-container">
                <div class='tableauPlaceholder' id='viz1769411780219' style='position: relative'>
                    <noscript>
                        <a href='#'>
                            <img alt='Dashboard 1 ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Ta&#47;Tableau_17693874392490&#47;Dashboard1&#47;1_rss.png' style='border: none' />
                        </a>
                    </noscript>
                    <object class='tableauViz' style='display:none;'>
                        <param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' />
                        <param name='embed_code_version' value='3' />
                        <param name='site_root' value='' />
                        <param name='name' value='Tableau_17693874392490&#47;Dashboard1' />
                        <param name='tabs' value='no' />
                        <param name='toolbar' value='yes' />
                        <param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Ta&#47;Tableau_17693874392490&#47;Dashboard1&#47;1.png' />
                        <param name='animate_transition' value='yes' />
                        <param name='display_static_image' value='yes' />
                        <param name='display_spinner' value='yes' />
                        <param name='display_overlay' value='yes' />
                        <param name='display_count' value='yes' />
                        <param name='language' value='en-US' />
                    </object>
                </div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1769411780219');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    if ( divElement.offsetWidth > 800 ) {
                        vizElement.style.width='100%';
                        vizElement.style.height='900px';
                    } else if ( divElement.offsetWidth > 500 ) {
                        vizElement.style.width='100%';
                        vizElement.style.height='850px';
                    } else {
                        vizElement.style.width='100%';
                        vizElement.style.height='1000px';
                    }
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>

            <div class="dashboard-links">
                <a href="https://public.tableau.com/app/profile/aiden.jajo/viz/Tableau_17693874392490/Dashboard1" class="btn btn-secondary" target="_blank">Open in Tableau Public ‚Üí</a>
            </div>
        </div>
    </section>

    <!-- Impact & Takeaways Section -->
    <section class="project-section bg-light">
        <div class="container">
            <h2 class="section-title-small">Impact & Takeaways</h2>

            <div class="takeaway-grid">
                <div class="takeaway-card">
                    <h3>For Policymakers</h3>
                    <ul>
                        <li>$885M from insulin alone justifies immediate policy intervention</li>
                        <li>Geographic targeting offers concentrated ROI in underperforming states</li>
                        <li>Systemic barriers are fixable through targeted prescriber and patient education</li>
                    </ul>
                </div>

                <div class="takeaway-card">
                    <h3>For Healthcare Systems</h3>
                    <ul>
                        <li>Generic substitution protocols could save billions system-wide</li>
                        <li>Pharmacy-level interventions show high potential for impact</li>
                        <li>Provider feedback systems work for changing prescribing behavior</li>
                    </ul>
                </div>

                <div class="takeaway-card">
                    <h3>For Patients</h3>
                    <ul>
                        <li>Ask your doctor about generic alternatives for every prescription</li>
                        <li>Geographic location affects your likelihood of receiving generics</li>
                        <li>Cost barriers to essential medications like insulin are solvable</li>
                    </ul>
                </div>
            </div>

            <div class="limitations">
                <h3>Limitations & Future Work</h3>
                <p><strong>Clinical equivalency assumption.</strong> This analysis assumes that every brand prescription could be switched to its generic equivalent without affecting patient outcomes. For small-molecule drugs, this is well-supported by FDA bioequivalence standards. For insulin and other biologics, the picture is more nuanced. Biosimilars are not chemically identical to reference products, and some patients may experience different responses. The insulin savings figures ($885M) should be understood as an upper bound that assumes full interchangeability.</p>
                
                <p><strong>What the data cannot tell us.</strong> The CMS dataset captures cost, claims volume, and geography, but not the reasons behind prescribing decisions. I cannot distinguish between brand prescriptions driven by clinical preference, insurance requirements, patient requests, or simply default prescribing habits. Prescriber-level data would be needed to separate these factors. Additionally, the dataset does not include patient outcome information, so I cannot directly validate that generic substitution maintains quality of care in practice.</p>
                
                <p><strong>Savings model assumptions.</strong> The 25% adoption improvement scenario assumes generic pricing remains stable as substitution volume increases. In practice, large-scale shifts in demand could affect generic pricing, potentially reducing per-claim savings. The model also assumes no additional friction costs (e.g., prior authorization delays, therapeutic monitoring) associated with switching. These factors would likely reduce, but not eliminate, the identified savings opportunity.</p>
                
                <p><strong>Future directions.</strong> The most impactful extensions of this work would be: (1) tracking generic adoption trends year-over-year to identify whether market forces are already narrowing the gap; (2) analyzing prescriber-level patterns to identify specific high-brand-preference providers for targeted outreach; (3) integrating FDA biosimilar approval timelines to model how new generic entries may shift the opportunity landscape; and (4) incorporating socioeconomic and demographic factors that may correlate with both prescribing patterns and patient health outcomes.</p>
            </div>
        </div>
    </section>

    <!-- Technical Implementation Section -->
    <section class="project-section">
        <div class="container">
            <h2 class="section-title-small">Technical Implementation</h2>

            <div class="tech-code-section">
                <h3>Core Savings Calculation</h3>
                <p>The heart of the analysis: organizing raw prescriber data by drug and brand/generic status, then computing per-claim cost differences and projecting savings scenarios.</p>
                <div class="code-block">
                    <pre><code># Organize prescriber-level data by drug and brand/generic status
drug_summary = df.groupby(['Gnrc_Name', 'Is_Brand']).agg(
    Total_Cost=('Tot_Drug_Cst', 'sum'),
    Total_Claims=('Tot_Clms', 'sum'),
    Total_Benes=('Tot_Benes', 'sum')
).reset_index()

# Pivot to get brand and generic metrics side by side
brand = drug_summary[drug_summary['Is_Brand'] == True].set_index('Gnrc_Name')
generic = drug_summary[drug_summary['Is_Brand'] == False].set_index('Gnrc_Name')

# Only analyze drugs that have BOTH brand and generic versions
common_drugs = brand.index.intersection(generic.index)

# Calculate average cost per claim and the savings difference
savings_df['Avg_Cost_Brand'] = brand.loc[common_drugs, 'Total_Cost'] / brand.loc[common_drugs, 'Total_Claims']
savings_df['Avg_Cost_Generic'] = generic.loc[common_drugs, 'Total_Cost'] / generic.loc[common_drugs, 'Total_Claims']
savings_df['Cost_Difference'] = savings_df['Avg_Cost_Brand'] - savings_df['Avg_Cost_Generic']

# Project savings: what if every brand claim switched to generic pricing?
savings_df['Potential_Savings_100pct'] = brand.loc[common_drugs, 'Total_Claims'].values * savings_df['Cost_Difference']
# Conservative 25% adoption improvement scenario
savings_df['Potential_Savings_25pct'] = savings_df['Potential_Savings_100pct'] * 0.25</code></pre>
                </div>
            </div>

            <div class="tech-details">
                <div class="tech-item">
                    <h3>Data Pipeline</h3>
                    <p>I loaded 3GB of raw CMS prescriber records using pandas, filtered to the 359 drugs with both brand and generic versions, then organized the data at both the national (per-drug) and state levels. I created new features including brand adoption rates, cost differences, and savings projections under multiple adoption scenarios.</p>
                    <div class="tech-tags">
                        <span class="tech-tag">pandas</span>
                        <span class="tech-tag">numpy</span>
                        <span class="tech-tag">3GB raw data</span>
                    </div>
                </div>

                <div class="tech-item">
                    <h3>Visualization</h3>
                    <p>I created static charts (top-10 rankings, cost distributions, state comparisons, opportunity scatter plot, waterfall) using matplotlib and seaborn for publication quality. I also built an interactive Tableau dashboard that enables filtering by state, medication, and cost metrics.</p>
                    <div class="tech-tags">
                        <span class="tech-tag">matplotlib</span>
                        <span class="tech-tag">seaborn</span>
                        <span class="tech-tag">Tableau Public</span>
                    </div>
                </div>
            </div>

            <div class="project-links">
                <a href="https://github.com/aidenjajo" class="btn btn-primary" target="_blank">View on GitHub ‚Üí</a>
                <a href="https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers" class="btn btn-secondary" target="_blank">Download CMS Data</a>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2026 Aiden B. Jajo. Built with purpose.</p>
        </div>
    </footer>
</body>
</html>
